Sirolimus in pediatric renal transplantation

Transplantation Proceedings

Volumn 37, Issue 2, 2005, Pages 682-684

  Ibanez J P ^a   Monteverde, M L ^a   Goldberg, J ^a   Diaz, M A ^a   Turconi, A ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID;

ADOLESCENT; CHILD; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CONFERENCE PAPER; DEATH; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EPSTEIN BARR VIRUS; FOLLOW UP; GINGIVA HYPERTROPHY; GLOMERULUS FILTRATION RATE; HERPES SIMPLEX; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LYMPHEDEMA; LYMPHOMA; MAJOR CLINICAL STUDY; NEOPLASM; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEINURIA; PSEUDOCYST; RECURRENT DISEASE; SEPSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION;

EID: 17844404537     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.12.242     Document Type: Conference Paper

References (15)

1. S. Hariharan, C. Johnson, B. Bresnahan Improved graft survival after renal transplantation in the United States, 1988 to 1996 N Engl J Med 342 2000 605
2. K. Mahalati, P. Belitsky, I. Sketris Neoral monitoring by simplified sparse sampling area under the concentration-time curve: Its relationship to acute rejection and Cyclosporine nephrotoxicity early after kidney transplantation Clin Transplant 68 1999 55
3. A. De Mattos, A. Olvaei, W. Bennett Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future Am J Kidney Dis 35 2000 333
4. C. Ponticelli Progression of renal damage in chronic rejection Kidney Int 57 suppl 75 2000 S-62
5. V. Dharnidharka, E. Sullivan, A. Tejani Risk factors for post-transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Cooperative Study (NAPRTCS) Transplantation 71 2001 1065
6. W. Harmon, V. Dharnidharka Lymphoproliferative disease in children Transplant Proc 31 1999 1268
7. S. Sehgal, J. Camardo, J. Scarola Rapamycin (sirolimus, rapamune) Curr Opin Nephrol Hyperten 4 1995 482
8. S. Sehgal Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression Clin Biochem 31 1998 335
9. Long-term improvement in renal function with Sirolimus after early Cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune maintenance regimen study. Transplantation 76:364, 2003
10. S. Flechner, D. Goldfarb, C. Modlin Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of Sirolimus versus Cyclosporine Transplantation 74 2002 1070
11. Sirolimus-based therapy following early Cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4:953, 2004
12. R. Sindhi Sirolimus in pediatric transplant recipients Transplant Proc 35 suppl 3A 2003 S113
13. MacDonald A for the Rapamune Global Study Group A worldwide, phase III, randomized, controlled, safety and efficacy study of a Sirolimus/Cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allograft Transplantation 71 2001 271
14. A. Schachter, K. Meyers, L. Spaneas Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol Pediatr Transplant 8 2004 171
15. C. Groth, L. Bäckman, J. Morales Sirolimus (Rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with Cyclosporine Clin Transplant 67 1999 1036